Latest news with #Niagen
Business Wire
4 days ago
- Health
- Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen ®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality. Niagen Bioscience Announces First Peer-Reviewed Study on NAD+ Supplement, Nicotinamide Riboside (NR), in Werner Syndrome Published by Niagen Bioscience Share The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally (GeneReviews), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression. Dr. Koshizaka noted, 'We hope our work will accelerate studies on not only WS but also other premature aging disorders and common age-related diseases—ultimately helping to extend health span and improve quality of life in both patients and the broader population.' Developing NAD+ Therapies for Rare, Age-Related Diseases This study builds on the growing body of clinical research demonstrating Niagen's potential in rare, age-related diseases (see Table 1 below). In Ataxia Telangiectasia (AT), Niagen has shown improvements in neurological function, coordination, and immune markers, including in pediatric populations. Rob Fried, CEO of Niagen Bioscience, stated, 'Rare disease research is a priority for Niagen Bioscience, particularly those indications associated with accelerated aging, mitochondrial dysfunction, or NAD+ deficiency.' The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to NR for the treatment of AT. These designations underscore the urgent unmet need and potential therapeutic value of Niagen in rare disease populations. Why NAD+ Matters in Rare Disease Scientific research has shown that declining NAD+ levels can contribute to age-related decline, mitochondrial dysfunction, and impaired DNA repair. In both Werner syndrome and AT, NAD+ deficiency appears to play a central role in disease progression (Fang et al., 2019). By restoring NAD+ levels, Niagen may help activate protective enzymes like SIRT1 and PARP1, reduce oxidative stress, and improve tissue function (Fang et al., 2016; Veenhuis et al., 2021; Presterud et al., 2023; Shoji et al., 2025; Lautrup et al., 2025). Vilhelm Bohr, M.D., Ph.D., former National Institute on Aging (NIA) Chief of the Laboratory of Molecular Genetics, and current Affiliate Professor in Genome Instability and Neurodegeneration at the University of Copenhagen and Scientific Advisor to Niagen Bioscience and coauthor on the study, commented, 'Werner syndrome is a rare genetic disorder that has long served as a valuable model for understanding the mechanisms of human aging. This study marks the first clinical trial using Niagen in those with Werner syndrome, and the findings—particularly improvements in cardiovascular markers—are promising. As Werner syndrome is a well-established model for normal aging, these results also suggest that NAD+ supplementation may support healthier aging in the broader population.' Study Highlights This 52-week randomized, double-blind, placebo-controlled crossover trial evaluated the safety and efficacy of oral Niagen supplementation in individuals with WS. The study randomized nine individuals (mean age: 47) who received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks. Key findings include: Robust increase in NAD+ levels: Niagen supplementation led to a ~140% increase in plasma NAD+ levels, compared to a ~4% decrease in the placebo group. Improved arterial stiffness: Niagen significantly improved cardio-ankle vascular index (CAVI), a measure of arterial stiffness. Cardioprotective lipid shift: Niagen increased the number of large HDL particles, indicating potential cardiovascular benefits. Wound healing support: Niagen reduced skin ulcer size and heel pad thinning, while ulcers worsened in the placebo group. Clinical safety profile: No moderate or severe adverse events were reported. Mild adverse events were fewer in individuals who received Niagen (7) compared to those who received placebo (12). Tolerability in complex individuals: Although mild liver enzyme elevations were noted, they were deemed manageable and consistent with underlying liver sensitivities common in Werner syndrome. This study represents the first clinical evaluation of Niagen in WS and supports further investigation of NAD+ augmentation as a therapeutic strategy in rare progeroid diseases. For additional information on the science supporting Niagen ®, visit Table 1 The table below provides an overview of the clinical research published to date on Niagen in rare age-related conditions. About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Xx Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Yahoo
4 days ago
- Health
- Yahoo
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+ augmentation with NR as a therapeutic strategy in rare progeroid diseases LOS ANGELES, June 09, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, shares positive results from a clinical study published in the peer-reviewed journal Aging Cell, by a team led by Masaya Koshizaka, M.D., Ph.D., Associate Professor, and Koutaro Yokote, M.D., Ph.D., MBA, President of Chiba University, both of the Center for Preventive Medical Sciences, Chiba University, and the Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital, Japan. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, Niagen®, in individuals with Werner syndrome (WS), a rare genetic disorder marked by rapid aging and premature mortality. The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS. Affecting approximately 1 in 380,000 to 1 in 1,000,000 people globally (GeneReviews), Werner syndrome is caused by mutations that impair DNA repair, leading to cellular aging decades ahead of normal progression. Dr. Koshizaka noted, "We hope our work will accelerate studies on not only WS but also other premature aging disorders and common age-related diseases—ultimately helping to extend health span and improve quality of life in both patients and the broader population." Developing NAD+ Therapies for Rare, Age-Related Diseases This study builds on the growing body of clinical research demonstrating Niagen's potential in rare, age-related diseases (see Table 1 below). In Ataxia Telangiectasia (AT), Niagen has shown improvements in neurological function, coordination, and immune markers, including in pediatric populations. Rob Fried, CEO of Niagen Bioscience, stated, "Rare disease research is a priority for Niagen Bioscience, particularly those indications associated with accelerated aging, mitochondrial dysfunction, or NAD+ deficiency." The U.S. Food and Drug Administration (FDA) previously granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation to NR for the treatment of AT. These designations underscore the urgent unmet need and potential therapeutic value of Niagen in rare disease populations. Why NAD+ Matters in Rare DiseaseScientific research has shown that declining NAD+ levels can contribute to age-related decline, mitochondrial dysfunction, and impaired DNA repair. In both Werner syndrome and AT, NAD+ deficiency appears to play a central role in disease progression (Fang et al., 2019). By restoring NAD+ levels, Niagen may help activate protective enzymes like SIRT1 and PARP1, reduce oxidative stress, and improve tissue function (Fang et al., 2016; Veenhuis et al., 2021; Presterud et al., 2023; Shoji et al., 2025; Lautrup et al., 2025). Vilhelm Bohr, M.D., Ph.D., former National Institute on Aging (NIA) Chief of the Laboratory of Molecular Genetics, and current Affiliate Professor in Genome Instability and Neurodegeneration at the University of Copenhagen and Scientific Advisor to Niagen Bioscience and coauthor on the study, commented, "Werner syndrome is a rare genetic disorder that has long served as a valuable model for understanding the mechanisms of human aging. This study marks the first clinical trial using Niagen in those with Werner syndrome, and the findings—particularly improvements in cardiovascular markers—are promising. As Werner syndrome is a well-established model for normal aging, these results also suggest that NAD+ supplementation may support healthier aging in the broader population." Study Highlights This 52-week randomized, double-blind, placebo-controlled crossover trial evaluated the safety and efficacy of oral Niagen supplementation in individuals with WS. The study randomized nine individuals (mean age: 47) who received 1,000 mg/day of Niagen or placebo for 26 weeks before crossing over to the alternate treatment for an additional 26 weeks. Key findings include: Robust increase in NAD+ levels: Niagen supplementation led to a ~140% increase in plasma NAD+ levels, compared to a ~4% decrease in the placebo group. Improved arterial stiffness: Niagen significantly improved cardio-ankle vascular index (CAVI), a measure of arterial stiffness. Cardioprotective lipid shift: Niagen increased the number of large HDL particles, indicating potential cardiovascular benefits. Wound healing support: Niagen reduced skin ulcer size and heel pad thinning, while ulcers worsened in the placebo group. Clinical safety profile: No moderate or severe adverse events were reported. Mild adverse events were fewer in individuals who received Niagen (7) compared to those who received placebo (12). Tolerability in complex individuals: Although mild liver enzyme elevations were noted, they were deemed manageable and consistent with underlying liver sensitivities common in Werner syndrome. This study represents the first clinical evaluation of Niagen in WS and supports further investigation of NAD+ augmentation as a therapeutic strategy in rare progeroid diseases. For additional information on the science supporting Niagen®, visit Table 1The table below provides an overview of the clinical research published to date on Niagen in rare age-related conditions. Publication Dose Duration Health Area Study Design Key Outcomes Shoji et al., 2025 1000 mg 52 weeks Werner syndrome Randomized, double-blind, placebo-controlled crossover study in 11 individuals with Werner syndrome ~140% increase in plasma NAD+ levels; improved arterial stiffness and reduced skin ulcer size. No moderate or severe adverse events reported. Presterud et al., 2023 500 mg 2 years Ataxia Telangiectasia (AT) Open-label, single-arm observational study in 10 AT individuals Significant improvements in motor coordination and eye movements. No serious adverse events. Longest NR supplementation trial to date. Veenhuis et al., 2021 25 mg/kg 4 months Ataxia Telangiectasia (AT) Open-label proof-of-concept study in 24 AT individuals Improved ataxia scores (SARA, ICARS); effects reversed after withdrawal. Increased IgG levels in immunodeficient individuals. Tinnevelt et al., 2020 25 mg/kg 4 months Ataxia Telangiectasia (AT) Comparative study in 14 individuals with AT NR-related pathways and metabolites significantly increased following NR supplementation. About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Xx Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: ICR, LLCReed Anderson(646) 277-1260Stephanie Carrington(646) 277-1282niagenir@
Business Wire
04-06-2025
- Business
- Business Wire
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference. Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference Share Mr. Fried is scheduled to participate in a fireside chat on Monday, Jun 9, from 2:15 p.m. to 2:50 p.m. Eastern Time (11:15 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors throughout the day. A replay of the webcast will be available following the event on the Niagen Bioscience Investor Relations website, For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States † (available at and Niagen Plus ™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).
Yahoo
05-05-2025
- Business
- Yahoo
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide
Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion LOS ANGELES, May 05, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics now offering pharmaceutical-grade Niagen® IV and injections featuring patented nicotinamide riboside. These new providers join a growing network of almost 600 clinics nationwide offering the first-of-its-kind, pharmaceutical-grade NAD-boosting Niagen IV therapy. For a list of all clinic providers, please visit Rob Fried, CEO of Niagen Bioscience, stated, "At the heart of the Niagen Plus ecosystem are our sterile pharmaceutical-grade Niagen NR formulations for IV as well as intramuscular (IM) and subcutaneous (SubQ) injections. These Niagen NR products are high-quality solutions for those seeking the most advanced, clinically supported NAD-boosting interventions." Some of the new clinic providers include: Arete (Nashville, TN) Beautologie (Bakersfield, CA) Beyond Remedi (Saint Paul, MN) Clarus Health (San Francisco, CA) PEAQ Society (Kansas City, MO) Energy4Life Centers (Park City, UT) Hydra Heal (Newport Beach, CA) Kahala Clinic (Honolulu, HI) LifeMed Institute (BelAir, MD; Columbia, MD; Rehoboth Beach, DE; Timonium, MD) Longevity LA (Los Angeles, CA) Navo (New York, NY) Outperforming NAD+ IV, Niagen IV is a significant advancement in NAD-boosting therapy. In a head-to-head comparison with NAD+ IV, Niagen IV offers superior tolerability, a 75% shorter infusion time, and a statistically significant 20% increase in whole blood NAD+ levels three hours after infusion, as measured by NAD+ dried blood spot tests (MedRxiv). Study results demonstrated that NAD+ IV had a longer infusion time and was associated with a high prevalence of uncomfortable side effects such as headaches, stomach pain, diarrhea, and nausea, which were not observed with Niagen IV. A common misconception is that the NAD+ molecule itself is bioavailable and that consumers can experience elevated NAD+ levels by taking NAD+ itself orally or intravenously. As a large, phosphorylated molecule, the NAD+ molecule cannot cross the cell membrane directly and must first be broken down into other NAD+ precursors, such as Niagen NR. Among various NAD+ precursors and the NAD+ molecule itself, Niagen is most efficient and effective at increasing NAD+ levels—it easily crosses the cell membrane directly and requires fewer steps for conversion into NAD+. Pharmaceutical-grade Niagen is compounded and distributed by 503B registered outsourcing facilities, including Wells Pharma of Houston, which adhere to stringent testing standards as required by the U.S. FDA, which ensures compliance with US Pharmacopoeia (USP) particulate matter and bacterial endotoxin guidelines. For more information on regulatory compliance and the scientific and quality standards behind Niagen, visit Arete Wellness, Beyond Remedi, Clarus Health, Energy4Life Centers, LifeMed Institute, Navo, and PEAQ Society highlight the benefits of Niagen IV: Adam Bobo, CRNA, Owner of Arete Wellness, noted, "At Arete Wellness in Nashville, our goal is to help clients enhance both athletic performance and overall wellness. Through extensive experience, we've found that Niagen IV is one of the most effective treatments available—whether you're a professional athlete or just someone looking to improve your health. Our athletes use it to support cellular recovery so they are at the top of their game. But it's not just for elite competitors—Niagen IV is perfect for anyone looking to boost their overall health and longevity. It's quickly become an essential part of the services we offer our clients." Marlee Dukek, Owner & RN at Beyond Remedi, shared, "Our clients are high-performing professionals, and they can't get enough of Niagen IV therapy—and for good reason. As driven individuals who demand peak performance from their minds and bodies, they appreciate how Niagen IV helps them recharge at a cellular level by boosting cellular energy and overall resilience. This allows them to tackle long days, intense schedules, and demanding decisions with greater ease and focus. Every client who has had both NAD+ IV and Niagen IV prefers Niagen IV for many reasons. We love how this product is benefiting our clients, and we have seen great success within our studio since offering this product." Anthony Kaveh, MD, Medical Director of Clarus Health in San Francisco, stated, "I recommend that patients with complex health needs, such as low energy levels, discomfort, or brain health concerns, integrate Niagen IV into their treatment plans. The side effect profile is very favorable, and this molecule can provide results to patients who have struggled for years. The list of responsive conditions continues to grow, and with it, patient satisfaction and quality of life. With proper medical guidance, the Niagen stack can transform patient lives and restore hope, making it a valuable modality in our practice." Dr. Greg Eckel, Founder of Energy4Life Centers, Brain Regeneration Specialist, commented, "High performers don't have time to run on empty—and Niagen IV is an infusion to support cellular energy. As someone who has spent decades focusing on brain health, I've seen firsthand how NAD+ can change the game. Delivered intravenously, Niagen IV supports recovery and brain health in the face of physiological stress and burnout. For entrepreneurs pushing limits, this is next-level fuel for your most valuable asset—your brain." Dr. Randolph Whipps, MD, FACC of LifeMed Institute, said, "At LifeMed Institute, innovation and patient-centered care go hand-in-hand. We strive to be at the forefront of regenerative and preventative medicine, continuously offering cutting-edge treatments that enhance both health and vitality. We utilize many comprehensive tools, including hormone optimization, personalized medical-grade supplements, sexual vitality treatments, IV and peptide therapies, with extensive genetic and biomarker excited to announce that all five of our locations now offer Niagen IVs, pushes, and injections, a powerful addition to our wellness services. Our patients are thrilled with the experience, relying on it to boost cellular energy, recovery, and overall vitality. What makes this breakthrough therapy especially appealing is its convenience and flexibility. Whether you choose a 30-minute IV session, a quick 5-minute push, or a simple injection that can be administered in our office, Niagen IV makes supporting your cellular health easier than proud to offer this innovative solution that empowers our patients to revitalize their energy, enhance their well-being, and improve their quality of life. Consider investing in yourself with Niagen IV for a strong, healthy life." Kimberly Harrison, FNP-BC, medical director at Navo, remarked, "At Navo, we've seen just how powerful Niagen IV can be—our clients are experiencing a noticeable boost in overall wellness. As a company focused on delivering next-level results, we believe Niagen is set to fully replace traditional NAD IV therapy within the next two to three years—and possibly even sooner. It's a meaningful step forward in the future of wellness, and we're proud to be leading that shift." Dr. Patrick Russell, DC, Chiropractic Physician, Functional Medicine Specialist, and Co-Founder of PEAQ Society, stated, "As a specialist in athlete performance and recovery, I've tested countless therapies—but Niagen IV stands out as one of the most powerful IV formulations for elite competitors. My NFL athletes rely on it before every game to boost cellular energy and support recovery, helping them perform at their absolute impact is undeniable. Players report that their recovery is better supported, making it an essential part of our pre-game protocol. In fact, during a mid-season shortage of Niagen IV, some of my athletes chose to skip their IVs entirely rather than settle for a standard NAD+ IV—that's how much they trust this IV by Niagen Plus is more than just an IV—it's a game-changing tool for any athlete serious about longevity, recovery, and sustained high performance. If you're looking for an edge, this is it." For more information about Niagen IV, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward-Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends" "estimates," "plans," "potential," "possible," "probable," "believes" "seeks," "may," "will," "should," "could," "predicts," "projects," "continue," "would" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; and the risks and uncertainties associated with our business and financial condition in general. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: Ben ShamsianLytham Partners646-829-9701shamsian@ Sign in to access your portfolio
Business Wire
05-05-2025
- Health
- Business Wire
Niagen Bioscience Announces Pharmaceutical-Grade Niagen ® IV Is Now Available in Almost 600 Clinics Nationwide
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the continued expansion of its clinical footprint with additional new clinics now offering pharmaceutical-grade Niagen ® IV and injections featuring patented nicotinamide riboside. These new providers join a growing network of almost 600 clinics nationwide offering the first-of-its-kind, pharmaceutical-grade NAD-boosting Niagen IV therapy. For a list of all clinic providers, please visit Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide Share Rob Fried, CEO of Niagen Bioscience, stated, 'At the heart of the Niagen Plus ecosystem are our sterile pharmaceutical-grade Niagen NR formulations for IV as well as intramuscular (IM) and subcutaneous (SubQ) injections. These Niagen NR products are high-quality solutions for those seeking the most advanced, clinically supported NAD-boosting interventions.' Some of the new clinic providers include: Arete (Nashville, TN) Beautologie (Bakersfield, CA) Beyond Remedi (Saint Paul, MN) Clarus Health (San Francisco, CA) PEAQ Society (Kansas City, MO) Energy4Life Centers (Park City, UT) Hydra Heal (Newport Beach, CA) Kahala Clinic (Honolulu, HI) LifeMed Institute (BelAir, MD; Columbia, MD; Rehoboth Beach, DE; Timonium, MD) Longevity LA (Los Angeles, CA) Navo (New York, NY) Outperforming NAD+ IV, Niagen IV is a significant advancement in NAD-boosting therapy. In a head-to-head comparison with NAD+ IV, Niagen IV offers superior tolerability, a 75% shorter infusion time, and a statistically significant 20% increase in whole blood NAD+ levels three hours after infusion, as measured by NAD+ dried blood spot tests (MedRxiv). Study results demonstrated that NAD+ IV had a longer infusion time and was associated with a high prevalence of uncomfortable side effects such as headaches, stomach pain, diarrhea, and nausea, which were not observed with Niagen IV. A common misconception is that the NAD+ molecule itself is bioavailable and that consumers can experience elevated NAD+ levels by taking NAD+ itself orally or intravenously. As a large, phosphorylated molecule, the NAD+ molecule cannot cross the cell membrane directly and must first be broken down into other NAD+ precursors, such as Niagen NR. Among various NAD+ precursors and the NAD+ molecule itself, Niagen is most efficient and effective at increasing NAD+ levels—it easily crosses the cell membrane directly and requires fewer steps for conversion into NAD+. Pharmaceutical-grade Niagen is compounded and distributed by 503B registered outsourcing facilities, including Wells Pharma of Houston, which adhere to stringent testing standards as required by the U.S. FDA, which ensures compliance with US Pharmacopoeia (USP) particulate matter and bacterial endotoxin guidelines. For more information on regulatory compliance and the scientific and quality standards behind Niagen, visit Arete Wellness, Beyond Remedi, Clarus Health, Energy4Life Centers, LifeMed Institute, Navo, and PEAQ Society highlight the benefits of Niagen IV: Adam Bobo, CRNA, Owner of Arete Wellness, noted, 'At Arete Wellness in Nashville, our goal is to help clients enhance both athletic performance and overall wellness. Through extensive experience, we've found that Niagen IV is one of the most effective treatments available—whether you're a professional athlete or just someone looking to improve your health. Our athletes use it to support cellular recovery so they are at the top of their game. But it's not just for elite competitors—Niagen IV is perfect for anyone looking to boost their overall health and longevity. It's quickly become an essential part of the services we offer our clients.' Marlee Dukek, Owner & RN at Beyond Remedi, shared, 'Our clients are high-performing professionals, and they can't get enough of Niagen IV therapy—and for good reason. As driven individuals who demand peak performance from their minds and bodies, they appreciate how Niagen IV helps them recharge at a cellular level by boosting cellular energy and overall resilience. This allows them to tackle long days, intense schedules, and demanding decisions with greater ease and focus. Every client who has had both NAD+ IV and Niagen IV prefers Niagen IV for many reasons. We love how this product is benefiting our clients, and we have seen great success within our studio since offering this product.' Anthony Kaveh, MD, Medical Director of Clarus Health in San Francisco, stated, 'I recommend that patients with complex health needs, such as low energy levels, discomfort, or brain health concerns, integrate Niagen IV into their treatment plans. The side effect profile is very favorable, and this molecule can provide results to patients who have struggled for years. The list of responsive conditions continues to grow, and with it, patient satisfaction and quality of life. With proper medical guidance, the Niagen stack can transform patient lives and restore hope, making it a valuable modality in our practice.' Dr. Greg Eckel, Founder of Energy4Life Centers, Brain Regeneration Specialist, commented, 'High performers don't have time to run on empty—and Niagen IV is an infusion to support cellular energy. As someone who has spent decades focusing on brain health, I've seen firsthand how NAD+ can change the game. Delivered intravenously, Niagen IV supports recovery and brain health in the face of physiological stress and burnout. For entrepreneurs pushing limits, this is next-level fuel for your most valuable asset—your brain.' Dr. Randolph Whipps, MD, FACC of LifeMed Institute, said, 'At LifeMed Institute, innovation and patient-centered care go hand-in-hand. We strive to be at the forefront of regenerative and preventative medicine, continuously offering cutting-edge treatments that enhance both health and vitality. We utilize many comprehensive tools, including hormone optimization, personalized medical-grade supplements, sexual vitality treatments, IV and peptide therapies, with extensive genetic and biomarker testing. We're excited to announce that all five of our locations now offer Niagen IVs, pushes, and injections, a powerful addition to our wellness services. Our patients are thrilled with the experience, relying on it to boost cellular energy, recovery, and overall vitality. What makes this breakthrough therapy especially appealing is its convenience and flexibility. Whether you choose a 30-minute IV session, a quick 5-minute push, or a simple injection that can be administered in our office, Niagen IV makes supporting your cellular health easier than ever. We're proud to offer this innovative solution that empowers our patients to revitalize their energy, enhance their well-being, and improve their quality of life. Consider investing in yourself with Niagen IV for a strong, healthy life.' Kimberly Harrison, FNP-BC, medical director at Navo, remarked, "At Navo, we've seen just how powerful Niagen IV can be—our clients are experiencing a noticeable boost in overall wellness. As a company focused on delivering next-level results, we believe Niagen is set to fully replace traditional NAD IV therapy within the next two to three years—and possibly even sooner. It's a meaningful step forward in the future of wellness, and we're proud to be leading that shift." Dr. Patrick Russell, DC, Chiropractic Physician, Functional Medicine Specialist, and Co-Founder of PEAQ Society, stated, 'As a specialist in athlete performance and recovery, I've tested countless therapies—but Niagen IV stands out as one of the most powerful IV formulations for elite competitors. My NFL athletes rely on it before every game to boost cellular energy and support recovery, helping them perform at their absolute peak. The impact is undeniable. Players report that their recovery is better supported, making it an essential part of our pre-game protocol. In fact, during a mid-season shortage of Niagen IV, some of my athletes chose to skip their IVs entirely rather than settle for a standard NAD+ IV—that's how much they trust this treatment. Niagen IV by Niagen Plus is more than just an IV—it's a game-changing tool for any athlete serious about longevity, recovery, and sustained high performance. If you're looking for an edge, this is it.' For more information about Niagen IV, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen ®, the number one NAD+ boosting oral supplement in the United States † (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. Forward-Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as 'expects,' 'anticipates,' 'intends' 'estimates,' 'plans,' 'potential,' 'possible,' 'probable,' 'believes' 'seeks,' 'may,' 'will,' 'should,' 'could,' 'predicts,' 'projects,' 'continue,' 'would' or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: inflationary conditions and adverse economic conditions; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain and grow sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; risks of unanticipated developments in and risks related to the Company's ability to secure adequate quantities of pharmaceutical-grade Niagen in a timely manner; the Company's ability to obtain appropriate contracts and arrangements with U.S. FDA-registered 503B outsourcing facilities required to compound and distribute pharmaceutical-grade Niagen to clinics; the Company's ability to remain on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act Category 1 list; the Company's ability to maintain and enforce the Company's existing intellectual property and obtain new patents; whether the potential benefits of NRC can be further supported; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other governmental authorities; and the risks and uncertainties associated with our business and financial condition in general. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).
